
    
      Following a Screening period of up to 21 days, eight (8) subjects in each cohort, 6 subjects
      randomized to CTP-730 and 2 subjects randomized to placebo, will be admitted to the clinical
      research unit (CRU) on the evening before dosing and remain sequestered at the study site
      until after the last inpatient blood sample is collected at 48 hours.
    
  